In the 1970s and 1980s it became evident that progression of renal disease and blood pressure are correlated. Subsequently, it was shown that antihypertensive treatment, especially with agents that block the renin-angiotensin system (RAS), could slow the progression of diabetic renal disease. Several studies, particularly with RAS blockers, have confirmed beneficial effects on urinary albumin excretion in patients with diabetes and microalbuminuria or proteinuria. There are good reasons to explore dual blockade of the RAS with an AT 1 -receptor blocker and an ACE inhibitor. Receptor blockers may block the effects of angiotensin II more effectively than ACE inhibitors; moreover, ACE inhibitors increase bradykinins which may have positive effects on blood pressure and renal function. Such combination treatment has been found to be well tolerated and more effective in reducing blood pressure than either
Introduction
A number of epidemiological studies have revealed a close correlation between the progression of renal disease and blood pressure levels in patients with type 1 and type 2 diabetes. 1, 2 Concomitantly, new antihypertensive and renal protective therapies have been developed; in particular, attention has focused on blocking the renal renin-angiotensin-aldosterone system (RAS). [3] [4] [5] It is increasingly recognised that the blood pressure reduction and blockade of the RAS may also be of benefit in other organs, including the heart and the brain. [6] [7] [8] [9] [10] Moreover, blockade of the RAS using an angiotensin converting enzyme (ACE) inhibitor was found to reduce cardiovascular mortality in patients at high cardiovascular risk. 9, 10 The present review will outline recent studies with angiotensin II type 1 (AT 1 ) receptor blockers in type 2 diabetes and diabetic complications such as hypertension, microalbuminuria or overt renal disease.
During the last decades there has been a change in the profile of patients in dialysis units towards more patients with type 2 diabetes and relatively fewer patients with type 1 diabetes. 11 Indeed, we have seen a surprising development over the past 20-30 years in that an increasing number of patients have developed end-stage renal disease due to type 2 diabetes, making diabetes type 2 the predominant cause of renal failure in dialysis patients. [11] [12] [13] Patients with diabetes display a large spectrum of renal abnormalities starting with normo-to microor macroalbuminuria (Table 1) . There has been a great impetus to identify patients with microalbuminuria because these patients have significantly increased risk, not only for the development of overt renal disease but also for cardiovascular disease and mortality. In addition, renal function in these patients is usually well preserved but a number of associated cardiovascular risk factors, such as hypertension and dyslipidaemia, are usually present (Table 1) . Genetic analysis has not been useful in identifying such patients and is therefore not yet indicated in the clinical setting.
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How to diagnose diabetic renal disease
The correct diagnosis of diabetic renal disease in patients with type 2 diabetes is essential; fortunately, the procedures to accomplish this are generally very simple and only very rarely is a renal biopsy necessary. After the diagnosis and treatment of hyperglycaemia. Abnormal albuminuria is usually not present. The 'silent stage' GFR may decrease slightly with better glycaemic control, but is still 'normal'.
Blood pressure has a tendency to increase.
Stage 3a:
Microalbuminuria may be present at diagnosis due to the fact that diabetes has been undiagnosed for years.
Stage 3b:
Microalbuminuria, however, typically develops from normoalbuminuria after some years with diabetes, due to blood pressure elevation and sub-optimal glycaemic control.
Hypertension and dyslipidaemia are quite common in such patients.
GFR is still normal, but tends to decrease. In some studies a tendency towards decreasing GFR has been found with high normoalbuminuria.
Stage 4:
Proteinuria typically occurs after 10-15 years with diabetes. Overt diabetic GFR declines variably, due to poor metabolic control and blood pressure. The risk factors are nephropathy hyperglycaemia, and especially hypertension. Even borderline abnormalities should be aggressively treated.
Blood pressure should be reduced to values as low as possible.
Cardiovascular disease is common.
On biopsy these patients typically have lesions but a small proportion do not show any changes initially. Non-diabetic renal disease or lesions are rare.
Retinopathy is often found, but is not a consistent feature.
Stage 5:
The late stage, just before or with renal insufficiency. that the patient actually has diabetes. This is usually based upon the medical history, treatment, blood glucose measurements and glycosylated haemoglobin (HbA1c) levels.
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In the presence of diabetes, it is mandatory to examine the patient for other vascular diabetic lesions, primarily retinopathy. It may seem surprising that retinopathy is not always found in type 2 diabetic patients with microalbuminuria or frank proteinuria, 17, 18 in contrast to type 1 diabetes. It is noteworthy that some patients may already have signs of renal disease, as well as evidence of retinopathy, at the time of diagnosis. This is due to the fact that diabetes may have been present for some time prior to diagnosis, since symptoms are usually mild or absent. 17 Valid measurements of all levels of albuminuria are essential, and usually it is necessary to perform two or three tests at intervals of some weeks or months to establish a diagnosis.
1,18-20 Usually, patients are followed longitudinally and it is possible to observe a slow increase in albuminuria (usually 10-20% per year) in these patients. 21 This increase is related to blood pressure and glycaemic control, and in patients with high blood pressure and poor glycaemic control there is often rapid progression.
1,2 The clinician should therefore ensure that blood pressure and glycaemic control is as good as possible.
Regarding measurements of renal function, it is usually sufficient to measure serum creatinine, although exact measurements of glomerular filtration rate (GFR), for example by Cr-EDTA or creatinine clearance, may be warranted in some cases. Blood pressure is often moderately elevated in these patients, and so careful measurement of blood pressure is always warranted. Hypertension is some- times related to sodium retention, and therefore careful clinical examination and treatment of fluid retention and measurement of urinary sodium excretion are important. Measurements of serum lipid levels are also warranted, although this parameter is less valuable in determining the treatment of kidney disease, compared with cardiovascular disease, where the benefits have been clearly shown in the recent British Heart Protection Study. 22 Therefore, careful cardiac and vascular examination is also part of the general examination strategy because cardiovascular disease is common in diabetic patients and is often related to the presence of microalbuminuria.
9,10
Microalbuminuria in type 2 diabetes
In type 2 diabetes, microalbuminuria is clearly predictive of increased mortality, as shown in many studies. 23 A number of trials have been conducted showing that microalbuminuria can be reduced, but studies including hard end points are sparse. However, the HOPE study suggested that cardiovascular end points could be reduced by ACE inhibition in these patients. 9, 10 The AT 1 -receptor blockers were developed later and have been shown to produce a reduction in microalbuminuria in diabetic patients (Table 2) .
Microalbuminuria is correlated to the duration of diabetes and level of glycaemia, and also to blood pressure elevation; it may be present at diagnosis, particularly in type 2 diabetes. Loss of autoregulation in the kidney may also play an important role in the genesis of diabetic renal disease because the systemic blood pressure is transferred more directly to the glomeruli. 31, 32 The best possible glycaemic control is important in patients with microalbuminuria, although antihypertensive treatment may be even more essential for the prevention of renal damage in such patients. It may well be that we should now strive for even lower blood pressure levels than previously believed, possibly as low as 120/75 mm Hg. Several studies have shown that ACE inhibitors and AT 1 -receptor blockers are effective in the treatment of these patients (Tables 2 and 3 ), although combination therapy with additional drugs may be necessary to achieve and maintain the best possible blood pressure control.
Inhibiting the renin-angiotensin system is a very efficient treatment strategy both for reducing blood pressure and for controlling microalbuminuria. However, ACE inhibition does not produce complete blockade of the renin-angiotensin system, due to the existence of alternative pathways of angiotensin II formation. 39 Recently, a new treatment strategy has been proposed that uses dual blockade with ACE inhibitors and AT 1 -receptor blockers. 3, 4, 26 Several studies have thus shown that the addition of an AT 1 -receptor blocker to an ACE inhibitor leads to further reductions in blood pressure and urinary albumin excretion (Table 3, Figure   Figure 1 Mean (± s.e.) seated systolic and diastolic blood pressure in patients with type 2 diabetes mellitus, hypertension and microalbuminuria before and during treatment with candesartan, 16 mg once daily (n=49), lisinopril, 20 mg once daily (n = 46), or their combination (n=49). The combination therapy group received monotherapy with either candesartan or lisinopril for the first 12 weeks. Reproduced from Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444, with permission from the BMJ Publishing Group.
Journal of Human Hypertension 1). For example, addition of candesartan to an ACE inhibitor in hypertensive patients with type 2 diabetes was found to be effective both in patients with microalbuminuria and in patients with proteinuria. 26, 36 Blocking the aldosterone system may also be beneficial. [40] [41] [42] There is also a strong case for the use of ␤-blockers. Unawareness of hypoglycaemia is extremely rare in type 2 diabetes, and so concerns about ␤-blockers are not relevant for most patients. On the contrary, many patients need ␤-blockers for cardiac protection against dysrhythmia and heart failure. Combination therapy with calcium channel blockers is also useful, but unless there is a compelling indication to use these agents as first-line therapy, it may be more appropriate to use them as a supplement (Figure 2) .
The major objective of antihypertensive treatment is to achieve a decline in blood pressure and albuminuria, while maintaining a stable serum creatinine. In practice there seems to be no lower limit for blood pressure, and if a level of 120/75 mm Hg can be achieved, this may be very useful in terms of renal and cardiovascular protection. To date there is no evidence of a so-called J-shaped curve in diabetic patients. 1, 2 There is little evidence that treatment of dyslipidaemia will offer any protection of renal function, and the few studies that do exist are somewhat conflicting. [43] [44] [45] [46] Obviously, treatment of dyslipidaemia is more important for the prevention of cardiac and vascular disease. 22 Only a few studies have assessed the use of lowprotein diets in diabetic patients. 47 Studies to date Figure 2 Multifactorial antihypertensive treatment in type 2 diabetes. As noted in the American Diabetes Association recommendations, 5 several drugs may be needed for the treatment of hypertension, and for cardiovascular and renal protection. ACE inhibitors are a useful choice in type 1 diabetes. In type 2 diabetes, AT 1 -receptor blockers may be preferred, but ACE inhibitors can also be used. The CALM Study has shown that the combination of these agents may be beneficial. 26 ␤-blockers may also be useful, as shown in the United Kingdom Prospective Diabetes Study (UKPDS). 7, 8 Diuretics are useful for eliminating oedema and reducing blood pressure, if salt restriction is not sufficient. Calcium antagonists are useful in combination, as for example in the RENAAL Study, 52 but are not appropriate for firstline therapy. Spironolactone may be used for more complete blockade of the renin-angiotensin-aldosterone system. 42 have not yielded positive results in patients with type 2 diabetes. 48 A low-protein diet may therefore not be warranted, but it may be useful to introduce a low-sodium diet, especially if the patient does not respond to conventional therapy. 49, 50 Cigarette smoking is also considered a risk factor and patients should be given advice regarding smoking cessation. 51 
Treatment strategy in proteinuric patients with type 2 diabetes
It is generally agreed that the same therapeutic measures are beneficial both in proteinuric and microalbuminuric patients. Two recent studies, the RENAAL and the IDNT Studies ( Table 4 ) have shown that treatment with an AT 1 -receptor blocker can postpone end-stage renal disease in patients with proteinuria and type 2 diabetes. 52, 53 However, the prognosis is still poor for these patients, and therefore it is important to screen for microalbuminuria in order to identify patients at risk as early as possible.
The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study 52 involved 1513 patients who were treated with losartan, 50-100 mg, or placebo in addition to conventional antihypertensive therapy. The incidence of a doubling of serum creatinine was reduced by 25%, and that of end-stage renal disease by 28%, in patients receiving the AT 1 -receptor blocker, and these effects were greater than those expected from blood pressure reduction alone (Table 4) . However, in his study, AT 1 -receptor blockade had no significant effect on mortality (Table 4) . Similar results were obtained in the IDNT (Irbesartan Diabetic Nephropathy Trial), 53 in which 1715 patients were randomised to receive irbesartan, 300 mg, amlodipine, 10 mg, or placebo for a mean of 2.6 years. The incidence of a composite end point of a doubling of serum creatinine, the development of end-stage renal disease, or death from any cause was significantly lower in patients receiving the AT 1 -receptor blocker than in either of the other two groups ( Table 4 ). The incidence of the two renal end points was also significantly reduced in the irbesartan group, compared with the other groups, but there was no significant difference in overall mortality between the groups (Table 4) .
In summary, therefore, the results of the RENAAL study may be somewhat more encouraging than the IDNT study, but in principle the two studies were of similar design and gave comparable results ( Table  4 ). The IDNT study also included patients who were treated with a calcium channel blocker, which produced similar results to placebo, and indeed the AT 1 -receptor blockers were more successful in preventing or postponing the course of renal disease. 52, 53 The RENAAL study also showed a beneficial effect on hospitalisation for cardiac failure. These studies included the best possible blood pressure control as background therapy.
In the IRMA-II (Irbesartan in patients with type 2 diabetes and Microalbuminuria) Study, 29 590 patients with hypertension and microalbuminuria were treated for 2 years with irbesartan, 150-300 mg, or placebo. The time to the onset of diabetic nephropathy, defined as persistent albuminuria in overnight urine specimens, was significantly prolonged in patients receiving the AT 1 -receptor blocker, but there was no effect on the fall in GFR. Theoretically it seems preferable to treat the patients as early as possible, perhaps even before microalbuminuria has developed. There is evidence to suggest that renal disease in diabetes is a selfperpetuating process, and that with more advanced disease there may be a gradual loss of autoregulation and unhindered transmission of the systemic blood pressure to glomeruli.
In addition to RAS blockade, lipid-lowering treatment is clearly important in diabetic patients, although no clinical trial has focused on renal end points. Further studies are needed in this area. 25, 54, 55 
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